Jagsonpal Pharmaceuticals is currently trading at Rs. 341.00, up by 7.70 points or 2.31% from its previous closing of Rs. 333.30 on the BSE.
The scrip opened at Rs. 337.00 and has touched a high and low of Rs. 347.45 and Rs. 337.00 respectively. So far 2073 shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 5 has touched a 52 week high of Rs. 513.90 on 31-Jul-2023 and a 52 week low of Rs. 270.05 on 14-Mar-2024.
Last one week high and low of the scrip stood at Rs. 368.25 and Rs. 330.95 respectively. The current market cap of the company is Rs. 881.27 crore.
The promoters holding in the company stood at 68.09%, while Institutions and Non-Institutions held 1.58% and 30.33% respectively.
Jagsonpal Pharmaceutical has launched MemUp, India’s first hormone replacement therapy (HRT) featuring USFDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule. MemUp marks a significant advancement in women’s healthcare, offering a ground-breaking solution for the management of vasomotor symptoms of menopause like hot flashes, night sweats and sleep issues.
MemUp is designed to specifically address this gap and support the urgent need for innovative and effective treatments. The unique combination mimics the body’s natural hormones, providing a more balanced and natural approach to HRT. This innovative formulation not only simplifies the treatment regimen but also enhances patient compliance and outcomes. MemUp will be made available at retailers across the country and can be purchased on the submission of a valid prescription issued by a Registered Medical Practitioner.
Jagsonpal Pharmaceutical is among India’s premiere pharmaceutical companies. The company has substantial research and development, manufacturing, marketing and distribution facilities.